- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04604197
ANGiographic Evaluation of Left Main Coronary Artery INtErvention (ANGELINE)
January 9, 2023 updated by: Fundación EPIC
To assess if an angiographic follow-up at 6 months after Percutaneous Coronary Intervention in Left Main Coronary Artery Disease decrease the composite objective of death, myocardial infarction, and stroke at 36 months.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Percutaneous coronary intervention (PCI) with drug-eluting stents in left main (LM) disease has demonstrated similar results than surgical revascularization in patients with SYNTAX score < 33, being the main drawback of PCI a higher rate of new revascularization.
A small study found a reduction in the composite end-point of cardiac death, myocardial infarction and urgent revascularization with a routine angiographic follow-up.
The investigators have designed a prospective, randomized, controlled, two-arm multicenter study in patients aged 18-85 with LM disease and SYNTAX score <33 and in cases ≥ 33 based on the Heart Team decision to assess the benefit of a routine angiographic follow-up 6 months after LM stenting.
After the index procedure and before hospital discharge the patient will be randomized to routine invasive angiographic follow-up at 6 months plus clinical follow-up at 6 months, 1, 2 and 3 years vs. the control arm, which would be followed clinically at 6 months, 1, 2 and 3 years.
Based on our calculations, an adequately powered trial would require 1009 patients per arm but due to the uncertainty of the results and the current economical restrictions we have designed a pilot study in 400 patients to find out the convenience of an adequately powered trial.
All the lesions should be treated with an everolimus eluting stent with permanent fluoropolymer.
It will be desirable to achieve complete revascularization and it will be highly recommended to perform the procedures guided with an intravascular image technique (OCT or IVUS (IntraVascular UltraSound) according to operator´s criteria).
The main outcome will be death, myocardial infarction and cerebrovascular accident at 3 years.
The initial percutaneous technique and the decision about the convenience and way of revascularization in case of restenosis in the follow-up will be left at the operator´s discretion, according in the most adequate way to the current guidelines.
Nonetheless, the investigators are strongly encouraged to rely on intravascular techniques, based on either imaging or physiology.
In those cases with in-stent hyperplasia with doubts about possible restenosis, FFR and RFR (Resting full-cycle ratio) will be performed, with low threshold to achieve a high rate of ruling out the restenosis.
Study Type
Interventional
Enrollment (Anticipated)
400
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: FUNDACION EPIC
- Phone Number: +34987876135
- Email: iepic@fundacionepic.org
Study Contact Backup
- Name: Iñigo Lozano, MD, PhD
- Phone Number: +34987876135
- Email: ilozano@fundacionepic.org
Study Locations
-
-
-
Albacete, Spain, 02006
- Recruiting
- Hospital General Universitario de Albacete
-
Alicante, Spain, 03010
- Recruiting
- Hospital General Universitario de Alicante
-
Alicante, Spain
- Recruiting
- Hospital Universitario San Juan de Alicante
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitari Vall d'Hebron
-
Barcelona, Spain, 08003
- Recruiting
- Hospital del Mar
-
Barcelona, Spain, 08907
- Recruiting
- Hospital Universitari Bellvitge
-
Ciudad Real, Spain, 13005
- Recruiting
- Hospital Universitario de Ciudad Real
-
Coruña, Spain, 15006
- Recruiting
- Hospital Universitario de A Coruna
-
Córdoba, Spain, 14004
- Recruiting
- Hospital Universitario Reina Sofia
-
Gijón, Spain, 33394
- Recruiting
- Hospital Universitario de Cabueñes
-
Granada, Spain, 18014
- Recruiting
- Hospital Universitario Virgen de las Nieves
-
Huelva, Spain, 21005
- Recruiting
- Hospital General Juan Ramon Jimenez
-
León, Spain, 24071
- Recruiting
- Hospital Universitario de Leon
-
Lugo, Spain, 27003
- Recruiting
- Hospital Universitario Lucus Agusti
-
Madrid, Spain, 28034
- Recruiting
- Hospital Universitario Ramon y Cajal
-
Madrid, Spain, 28041
- Recruiting
- Hospital Universitario 12 de Octubre
-
Madrid, Spain, 28046
- Recruiting
- Hospital Universitario La Paz
-
Madrid, Spain, 28006
- Recruiting
- Hospital Universitario La Princesa
-
Murcia, Spain, 30120
- Recruiting
- Hospital Universitario Virgen Arrixaca
-
Santander, Spain, 39008
- Recruiting
- Hospital Universitario Marques de Valdecilla
-
Santiago De Compostela, Spain, 15706
- Recruiting
- Hospital Clínico Universitario de Santiago de Compostela
-
Valencia, Spain, 46010
- Recruiting
- Hospital Clinico Universitario de Valencia
-
Valladolid, Spain, 47003
- Recruiting
- Hospital Clínico Universitario de Valladolid
-
Zaragoza, Spain, 50009
- Recruiting
- Hospital Clinico Universitario Lozano Blesa
-
Zaragoza, Spain, 50009
- Recruiting
- Hospital Universitario Miguel Servet
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Recruiting
- Hospital Universitari Germans Trias i Pujol
-
-
Bizkaia
-
Barakaldo, Bizkaia, Spain, 48903
- Recruiting
- Hospital Universitario de Cruces
-
-
Gipuzkoa
-
Donostia, Gipuzkoa, Spain, 20014
- Recruiting
- Hospital Universitario Donostia
-
-
Malaga
-
Málaga, Malaga, Spain, 29010
- Recruiting
- Hospital Universitario Regional de Malaga
-
-
Vizcaya
-
Galdakao, Vizcaya, Spain, 48960
- Recruiting
- Hospital Galdakao-Usansolo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: 18- 85 years at the date of the PCI.
- With PCI for presenting de novo lesions in the Left Main Artery by implanting a cobalt-chrome stent with everolimus-eluting fluoropolymer.
- Informed consent signed.
Exclusion Criteria:
- Refusal to participate in the study.
- Patients with left main disease who have been admitted with STEMI and have undergone primary angioplasty in a culprit lesion different than the left main. The left main lesion has been treated as a stage procedure and discharged with left ventricular ejection fraction < 35 %.
- Previous coronary surgery.
- Creatinine clearance <40 ml / min.
- Contraindication for double antiaggregation after PCI.
- Patients life expectancy <36 months.
- Included in other studies or clinical trials.
- Pregnant or lactating women.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Angiography and Clinical Follow up
After PCI.
The patient is randomized to an angiographic follow-up at 6 months and a Clinical Follow to 36 months
|
Angiography and Clinical Follow up
|
Active Comparator: Clinical Follow up
After PCI.
The patient is randomized to a Clinical Follow to 36 months
|
Clinical Follow up
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Composite endpoint: defined as : death, myocardial infarction, and stroke.
Time Frame: 36 months
|
Composite endpoint: defined as : death, myocardial infarction, and stroke.
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
All Death
Time Frame: 36 months
|
Occurrence of Death
|
36 months
|
Cardiac Death
Time Frame: 36 months
|
Occurrence of Cardiac Death
|
36 months
|
Myocardial Infarction
Time Frame: 36 months
|
Occurrence of Myocardial Infarction
|
36 months
|
Stroke
Time Frame: 36 months
|
Occurrence of Stroke
|
36 months
|
Stent thrombosis (ARC definite/probable)
Time Frame: 36 months
|
Occurrence of thrombosis (ARC definite/probable)
|
36 months
|
Major bleeding event (BARC type 2-5)
Time Frame: 36 months
|
Occurrence of Major bleeding event (BARC type 2-5)
|
36 months
|
Target Vessel revascularization.
Time Frame: 36 months
|
Occurrence of Target Vessel revascularization.
|
36 months
|
Revascularization by CABG ( Coronary Artery Bypass Grafting) or PCI (Percutaneous Coronary Intervention)
Time Frame: 36 months
|
Occurrence of New revascularization by CABG or PCI
|
36 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Cavalcante R, Sotomi Y, Lee CW, Ahn JM, Farooq V, Tateishi H, Tenekecioglu E, Zeng Y, Suwannasom P, Collet C, Albuquerque FN, Onuma Y, Park SJ, Serruys PW. Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease. J Am Coll Cardiol. 2016 Sep 6;68(10):999-1009. doi: 10.1016/j.jacc.2016.06.024.
- Puri R, de la Torre Hernandez JM, Auffret V. Routine Surveillance Coronary Angiography Post-PCI: Should We ReACT and Change Our Routine? JACC Cardiovasc Interv. 2017 Jan 23;10(2):118-120. doi: 10.1016/j.jcin.2016.11.020. Epub 2016 Dec 28. No abstract available.
- Aurigemma C, Burzotta F, Porto I, Niccoli G, Leone AM, Crea F, Trani C. Clinical impact of routine angiographic follow-up after percutaneous coronary interventions on unprotected left main. Cardiol J. 2018;25(5):582-588. doi: 10.5603/CJ.a2018.0092. Epub 2018 Aug 29.
- Stone GW, Sabik JF, Serruys PW, Simonton CA, Genereux P, Puskas J, Kandzari DE, Morice MC, Lembo N, Brown WM 3rd, Taggart DP, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogats G, Mansour S, Noiseux N, Sabate M, Pomar J, Hickey M, Gershlick A, Buszman P, Bochenek A, Schampaert E, Page P, Dressler O, Kosmidou I, Mehran R, Pocock SJ, Kappetein AP; EXCEL Trial Investigators. Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. N Engl J Med. 2016 Dec 8;375(23):2223-2235. doi: 10.1056/NEJMoa1610227. Epub 2016 Oct 31. Erratum In: N Engl J Med. 2019 Oct 31;381(18):1789.
- Makikallio T, Holm NR, Lindsay M, Spence MS, Erglis A, Menown IB, Trovik T, Eskola M, Romppanen H, Kellerth T, Ravkilde J, Jensen LO, Kalinauskas G, Linder RB, Pentikainen M, Hervold A, Banning A, Zaman A, Cotton J, Eriksen E, Margus S, Sorensen HT, Nielsen PH, Niemela M, Kervinen K, Lassen JF, Maeng M, Oldroyd K, Berg G, Walsh SJ, Hanratty CG, Kumsars I, Stradins P, Steigen TK, Frobert O, Graham AN, Endresen PC, Corbascio M, Kajander O, Trivedi U, Hartikainen J, Anttila V, Hildick-Smith D, Thuesen L, Christiansen EH; NOBLE study investigators. Percutaneous coronary angioplasty versus coronary artery bypass grafting in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial. Lancet. 2016 Dec 3;388(10061):2743-2752. doi: 10.1016/S0140-6736(16)32052-9. Epub 2016 Oct 31. Erratum In: Lancet. 2016 Dec 3;388(10061):2742.
- Stone GW, Kappetein AP, Sabik JF, Pocock SJ, Morice MC, Puskas J, Kandzari DE, Karmpaliotis D, Brown WM 3rd, Lembo NJ, Banning A, Merkely B, Horkay F, Boonstra PW, van Boven AJ, Ungi I, Bogats G, Mansour S, Noiseux N, Sabate M, Pomar J, Hickey M, Gershlick A, Buszman PE, Bochenek A, Schampaert E, Page P, Modolo R, Gregson J, Simonton CA, Mehran R, Kosmidou I, Genereux P, Crowley A, Dressler O, Serruys PW; EXCEL Trial Investigators. Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. N Engl J Med. 2019 Nov 7;381(19):1820-1830. doi: 10.1056/NEJMoa1909406. Epub 2019 Sep 28. Erratum In: N Engl J Med. 2020 Mar 12;382(11):1078.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 16, 2021
Primary Completion (Anticipated)
December 1, 2025
Study Completion (Anticipated)
December 1, 2025
Study Registration Dates
First Submitted
October 21, 2020
First Submitted That Met QC Criteria
October 21, 2020
First Posted (Actual)
October 27, 2020
Study Record Updates
Last Update Posted (Estimate)
January 11, 2023
Last Update Submitted That Met QC Criteria
January 9, 2023
Last Verified
January 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EPIC23-ANGELINE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
Clinical Trials on Angiography and Clinical Follow up
-
Takeshi MorimotoCompletedCoronary Artery DiseaseJapan
-
Second Affiliated Hospital, School of Medicine,...First Affiliated Hospital of Wenzhou Medical University; Jinhua Central Hospital and other collaboratorsRecruitingCoronary Artery DiseaseChina
-
University of IcelandMemorial Sloan Kettering Cancer Center; Landspitali University Hospital; deCODE... and other collaboratorsActive, not recruitingMonoclonal Gammopathy of Undetermined SignificanceIceland
-
Rennes University HospitalUnknown
-
M.D. Anderson Cancer CenterRecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingSpinocerebellar Ataxias | Inherited Movement Disorders | Hyperkinetic DisordersFrance
-
Oslo University HospitalCompletedSubarachnoid HemorrhageNorway
-
University of Cape TownMedical Research Council, South AfricaCompleted
-
M.D. Anderson Cancer CenterRecruitingCervical Large Cell Neuroendocrine Carcinoma | Cervical Neuroendocrine Carcinoma | Cervical Small Cell Carcinoma | Cervical Undifferentiated Carcinoma | Stage I Cervical Cancer AJCC v8 | Stage IA Cervical Cancer AJCC v8 | Stage IA1 Cervical Cancer AJCC v8 | Stage IA2 Cervical Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Federico II UniversityCompletedHodgkin Lymphoma | Relapse | High Risk